Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

U.K. biotech sells one ion channel program, keeps another

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while